More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.

Original title: “ArriVent collapses on disappointing lung cancer data”

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

Original title: “Merck, Daiichi end plans to seek speedy approval of lung cancer ADC”

Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.

Original title: “Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC”

decoding low density neutrophils in breast and lung cancer from bystanders to drivers

Original title: “Decoding Low-Density Neutrophils in Breast and Lung Cancer: From Bystanders to Drivers.”

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

Original title: “WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight”

Analysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is already under review for the the second-line setting, with a decision expected by early next year.

Original title: “Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit”

BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new findings for their closely watched programs, highlighting overall survival benefits in various types of lung cancer.

Original title: “Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs”

New data shows nearly three‑year median overall survival

Original title: “Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer”

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

Original title: “Akeso, Summit cancer drug confirms lung cancer survival benefit”

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy ... The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value. Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay. Targeted RAS inhibition has demonstrated clinical benefit in patients with RAS G12C non-small cell lung cancer following initial treatment with chemotherapy and immunotherapy, but there are no targeted therapies for patients with other RAS tumor mutations. The rates of objective response, disease control and survival observed in patients treated with RASONQUE in this Phase 1/2 study support the ongoing global, randomized pivotal RASolve 301 trial evaluating RASONQUE in previously treated RAS mutant non-small lung cancer. The 38-patient subgroup had median overall survival of 16.0 months; the global, randomized Phase 3 RASolve 301 trial in NSCLC is ongoing.

Original title: “An experimental lung cancer drug held disease in check for 89% of patients in one group.”

pole p286r mutated hepatoid adenocarcinoma of the lung showing substantial response to immune checkpoint inhibition

Original title: “A POLE P286R-Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition.”

sixty years of lung cancer screening from sputum cytology to low dose ct and the emerging precision era

Original title: “Sixty Years of Lung Cancer Screening: From Sputum Cytology to Low-Dose CT and the Emerging Precision Era.”

targeting egfr in lung cancer lessons in signal transduction and treatment induced mutagenesis

Original title: “Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.”

reappraisal of endobronchial polypoid adenocarcinoma of the lung a clinicopathological analysis of 11 cases

Original title: “Reappraisal of Endobronchial Polypoid Adenocarcinoma of the Lung: A Clinicopathological Analysis of 11 Cases.”

squamous cell carcinoma of the lung presenting as paraneoplastic antibody positive orbital myositis with review of literature

Original title: “Squamous cell carcinoma of the lung presenting as paraneoplastic antibody positive orbital myositis with review of literature.”

Radiopharm Theranostics is a clinical ... and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety ... Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 180mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positi Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors · Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution As we execute on our clinical development strategy, we remain focused on unlocking the full potential of RAD202 and generating meaningful data that could support a differentiated radiotherapeutic option for HER2-positive patients in need of new treatment alternatives.”

Original title: “Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - BioSpace”

Saffron trial delivers positive results

Original title: “Orpathys plus Tagrisso shows survival benefit in lung cancer”

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

Original title: “AstraZeneca scores in lung cancer; Sandoz inks a China deal”

AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.

Original title: “AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow”